MFW
LMDXW

Meristem Family Wealth’s LumiraDx Limited Warrant LMDXW Stock Holding History

Meristem Family Wealth’s Portfolio LMDXW Stock Details LMDXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,000
Closed -$49K – 397
2021
Q4 		$49K Hold
27,000
– – ﹤0.01% 387
2021
Q3 		$31K Buy
+27,000
New +$31.3K ﹤0.01% 415

Other funds holding LMDXW

CH
CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

Meristem Family Wealth's LMDXW Position: Q1 2022 in Review

Meristem Family Wealth sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2022, closing a stake of 27,000 shares — an estimated $49K sold.

Meristem Family Wealth first reported a position in LMDXW in Q3 2021 and held it in 2 quarters. The position peaked at $49K in Q4 2021. 20 funds tracked by Wall St. Rank hold LMDXW as of Q1 2022.

  • Meristem Family Wealth reported no remaining LumiraDx Limited Warrant position as of Q1 2022 after selling out during the quarter.
  • Meristem Family Wealth sold 27,000 LumiraDx Limited Warrant shares in Q1 2022, an estimated $49K.
  • Meristem Family Wealth first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 2 quarters.
  • Meristem Family Wealth's LumiraDx Limited Warrant position peaked at $49K in Q4 2021.
  • 20 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.